Research Article
Sex Differences of Human Cardiac Progenitor Cells in the Biological Response to TNF-α Treatment

Elisabetta Straface,1 Lucrezia Gambardella,1 Francesca Pagano,2 Francesco Angelini,2 Barbara Ascione,1 Rosa Vona,1 Elena De Falco,2 Elena Cavarretta,2 Raffaele La Russa,3,4 Walter Malorni,1 Giacomo Frati,2,5 and Isotta Chimenti2

1Center for Gender-Specific Medicine, Istituto Superiore di Sanità, Rome, Italy
2Department of Medical Surgical Sciences and Biotechnologies, “La Sapienza” University of Rome, Rome, Italy
3Department of Anatomical, Histological, Forensic and Orthopaedic Sciences, Sapienza University of Rome, Viale Regina Elena 336, 00185 Rome, Italy
4Malzoni Clinical-Scientific Institute (MaCSI), Via Carmelo Errico 2, 83100 Avellino, Italy
5Department of AngioCardioNeurology, IRCCS Neuromed, Pozzilli, Italy

Correspondence should be addressed to Elisabetta Straface; elisabetta.straface@iss.it

Received 23 February 2017; Revised 9 June 2017; Accepted 14 June 2017; Published 17 September 2017

Academic Editor: Leonard M. Eisenberg

Copyright © 2017 Elisabetta Straface et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Adult cardiac progenitor cells (CPCs), isolated as cardiosphere-derived cells (CDCs), represent promising candidates for cardiac regenerative therapy. CDCs can be expanded in vitro manyfolds without losing their differentiation potential, reaching numbers that are appropriate for clinical applications. Since mechanisms of successful CDC survival and engraftment in the damaged myocardium are still critical and unresolved issues, we aimed at deciphering possible key factors capable of bolstering CDC function. In particular, the response and the phenotype of CDCs from male and female donors, in terms of cell cycle progression and cell spreading, have also been assessed. The results obtained indicate that (i) the intracellular signaling activated in our experimental conditions is most likely due to the prosurvival and proliferative signaling of TNF-α receptor 2 and that (ii) cells from female patients appear more responsive to TNF-α treatment in terms of cell cycle progression and migration ability. In conclusion, the present report highlights the hypothesis that TNF-stimulated CDCs isolated from females may represent a promising candidate for cardiac regenerative therapy applications.

1. Introduction

Cardiovascular diseases remain the leading cause for morbidity/mortality in the Western world [1, 2]. Translational research and recent clinical trials suggest that adult stem/progenitor cell (S/PC) transplantation into the damaged myocardium (cell therapy) can improve cardiac function [3, 4]. To regenerate the heart and restore its function, many types of S/PCs are currently being explored, each with their own benefits and limitations. Cardiac cell therapy with S/PCs from extracardiac tissues (e.g., mesenchymal stem cells and bone marrow mononuclear cells) can decrease the death rate of endogenous myocytes and improve neoangiogenesis, probably by secretion of paracrine factors, such as several cytokines, chemokines, and growth factors [5]. These factors have been shown to reduce inflammation, decrease apoptotic cell death, and improve overall myocardial function [6]. Direct regeneration has been shown to be more efficient with the use of resident cardiac progenitor cells (CPCs) [7], which nonetheless exert paracrine effects [6, 8]. Adult CPCs are multipotent cells isolated from heart tissue obtained from patients undergoing surgery or catheterization and can be
isolated as spontaneous spheroids, named cardiospheres (CSs) [9]. These cells can be expanded in vitro manyfolds without losing their differentiation potential, reaching numbers that are appropriate for in vivo transplantation in patients [10]. CSs can be efficiently isolated even from advanced heart failure patients [11], and the only medical parameter described so far to significantly impair CS isolation efficiency and affect CS phenotype is beta-blocker assumption by tissue donors [12]. Despite promising preclinical and clinical results, several limitations still exist for cardiac cell therapy. In particular, the need to improve survival, differentiation, and engraftment of the transplanted stem cell population [13], even with resident CPCs [14], has been envisaged. Thus, the first step to optimize the repair of a damaged myocardium by transplanted S/PCS is to increase their survival. Insufficient homing and engraftment of transplanted cells into the ischemic milieu limit in fact the full potential of cell-based cardiac repair, and several approaches have been introduced to overcome these limitations, such as tissue engineering [15] or pharmacological pre-/postconditioning [16, 17].

Multiple molecules have been described to mediate the complex and hostile signals in diseased cardiac tissue during injury and remodeling. Among these, tumor necrosis factor alpha (TNF-α) seems to play a critical role. This is a potent multifunctional cytokine involved in a number of pathologies in the cardiovascular system, including heart failure, and associated with many diverse physiological and physiopathological opposite events, such as cell death by apoptosis, but also cell growth, differentiation, and cell survival depending on the dose [18]. In line with this, a dual role of TNF-α in the attenuation or in the aggravation of cardiac injury has been proposed. Paradoxically, it has in fact been reported that low levels of TNF-α can trigger a cardioprotective program via the well-described free radical signaling pathway [19], whereas high concentrations of this cytokine are responsible of its well-known proapoptotic and inflammatory cascades [20]. Concerning CS biology, multiple signaling pathways have been reported so far to affect their phenotype, including those related to thrombin [21], EGF [22], IGF1 and Wnt [23, 24], TGF-beta [25], and beta-adrenergic signaling [12, 26]. However, the influence of TNF-α on the biology of CPCs has not been thoroughly investigated yet.

Since abundant data from the literature underscore a significant disparity between men and women for the incidence and severity of cardiovascular diseases [27], several investigations aimed at elucidating the mechanisms underlying these differences have been carried out. It has been observed that men undergo more rapid progression of heart failure, less preservation of myocardial mass as they age, and worse age-matched cardiac contractility compared to women. However, the possible implication of CPCs in this disparity has been poorly investigated. For instance, sex-related differences in the abundance of resident CPCs have never been detected so far [11, 12, 28], and sex-related differences in the response to inflammatory signals have not been investigated yet. However, interestingly, a differential cardioprotective role of TNF-α has been described in mesenchymal stem cell (MSC) therapy based on the sex of MSC donors. In fact, MSCs from males seem to be more sensitive to TNF-α-mediated detrimental signals, that is, at high concentrations of the cytokine, than their female counterparts [29]. On the basis of these considerations, CPCs in the form of CS-derived cells from male and female donors have been exposed to low, nontoxic concentrations of TNF-α in order to investigate their differential biological response.

2. Materials and Methods

2.1. Cardiosphere and Cardiosphere-Derived Cell Isolation, Culture, and Treatments. Human auricula biopsies were obtained from nine patients (five males and four females) undergoing cardiac surgery for ischaemic cardiomyopathy, after informed consent and under protocol number 2154/15, approved by the Ethical Committee of the "Umberto I" Hospital, "La Sapienza" University of Rome. Available anthropometric and medical data are reported in Table 1. Donors were all under beta-blocker treatment [12]. CPCs were isolated with the standardized CS protocol, as previously described [30]. Briefly, after approximately 4 weeks of explant outgrowth on fibronectin-coated Petri dishes (BD Biosciences) in complete explant medium (CEM; IMDM medium (Gibco) supplemented with 1% penicillin-streptomycin, 1% L-glutamine, 0.1 mM 2-mercaptoethanol (Gibco), and 20% FBS (Lonza)), explant-derived cells (EDCs) were collected every 7 days (up to 3 times from each explant) and seeded on poly-D-lysine- (BD Biosciences) coated wells (7000 cells/cm²) to obtain CSs in CS-growth medium (CGM): 35% IMDM/65% DMEM/F-12 Mix (Gibco and Lonza), 3.5% FBS, 1% penicillin-streptomycin, 1% L-glutamine, 0.1 mM 2-mercaptoethanol (Gibco) and 25 ng/ml EGF (Peprotech), and 4 ng/ml cardiotoxin-1 (Peprotech). After 1 week, CSs were collected and expanded on fibronectin-coated surfaces in CEM as cardiosphere-derived cells (CDCs) and expanded for not more than three split rounds. Cells were treated with 100 ng/ml TNF-α (Sigma-Aldrich) for up to 48 hours.

2.2. Expression of TNF-α Receptors. To verify the expression of TNF-α receptor 1 (TNFR1) and TNF-α receptor 2 (TNFR2)
on the cell surface, cells were incubated with R-phycocerythrin-conjugated murine antibodies against human TNFR1 and TNFR2 (Caltag Laboratories, Burlingame, CA, USA). Samples were analyzed on a FACScan flow cytometer by using the Cell Quest software (Becton Dickinson, Mountain View, CA, USA).

2.3. Evaluation of the Redox State. Cells (5 × 10⁵) were incubated with 1 μmol/l of dihydroethidium (DHE, Molecular Probes) or 10 μmol/l of dihydrorhodamine 123 (DHR 123, Molecular Probes) for 15 minutes at 37°C. After washing, samples were analyzed on a FACScan flow cytometer by using the Cell Quest software (Becton Dickinson, Mountain View, CA, USA).

2.4. Evaluation of Apoptosis. Quantitative evaluation of apoptosis was performed by flow cytometry after double staining using fluorescein isothiocyanate-conjugated annexin V and 0.05% trypan blue for 10 minutes at room temperature and analyzed by flow cytometry in the FL1 and FL3 channels to determine the percentage of dead cells [31]. Samples were analyzed on a FACScan flow cytometer by using the Cell Quest software (Becton Dickinson, Mountain View, CA, USA).

2.5. Cell Cycle. Cell cycle analyses were conducted after 48 hours of TNF-α treatment. Cultured cells were treated with 1 mmol/l bromodeoxyuridine (BrdU; BD Immunocytometry Systems) for 30 minutes and fixed in 70% ice-cold ethanol. 1 × 10⁶ fixed cells were incubated in 3 N HCl for 20 minutes. After washing with 0.1 mol/l Na₂B₄O₇ (pH 8.5) to stop acid RNase (Sigma-Aldrich) for 30 minutes at 37°C, samples were analyzed on a FACScan flow cytometer for 15 minutes at 37°C. After washing, samples were analyzed on a FACScan flow cytometer by using the Cell Quest software (Becton Dickinson, Mountain View, CA, USA).

2.6. Analytical Cytology. For nuclear factor kappa B (NF-κB) detection, cells were fixed in acetone/methanol 1/1 (v/v) for 10 minutes at room temperature and air dried. After 1 hour of preincubation with PBS containing 10% of AB human serum, cells were incubated for 1 hour at room temperature with the rabbit polyclonal antibody to NF-κB (Santa Cruz Biotechnology). Following three washes in PBS, cells were incubated for 1 hour at room temperature with FITC-labeled anti-rabbit secondary antibody. Morphometric analyses were also employed to evaluate NF-κB nuclear translocation. The cells with positive nucleus were evaluated by counting 300 cells at high magnification (500x). The nuclei were stained with Hoechst 33258 (Sigma-Aldrich) at 37°C for 15 minutes. For actin filament detection, cells were fixed with 4% paraformaldehyde, permeabilized with 0.5% Triton X-100 (Sigma-Aldrich), and stained with fluorescein-conjugated phalloidin (Sigma-Aldrich) at 37°C for 30 minutes.

All samples were mounted on glass cover slips with glycerol/PBS (2:1) and observed by intensified video microscopy (IVM) with an Olympus Microphot fluorescence microscope (Olympus Corporation, Tokyo, Japan) equipped with a Zeiss CCD camera.

2.7. Scratch Assay. Cell migration was examined by scratch assay according to Liang et al. [32]. Approximately 2.5 × 10⁵ cells were seeded in 35 mm Petri dishes. When cells reached confluence, dishes were scratched with a sterile 200 μl pipette tip, treated or not with TNF-α, and incubated at 37°C.

Migration of cells towards wound closure of the same region at 0 and 24 hours was monitored, and images were acquired using a digital camera system coupled with an inverted microscope (Olympus IX-71). Repopulation by migrating cells of the wound region was then analyzed and quantified using the ImageJ v1.48 software (http://imagej.nih.gov/ij/).

2.8. Data Analysis and Statistics. Cytofluorimetric results were statistically analyzed by using the parametric Kolmogorov–Smirnov test using Cell Quest software. A least 20,000 events were acquired. The median values of fluorescence intensity histograms were used to provide a semiquantitative analysis. The results are displayed as average value ± standard deviation, unless otherwise specified. Significance of difference between any two groups was assessed by two-sided Student’s t-test. A threshold value of p < 0.05 was considered to be significant.

3. Results and Discussion

3.1. Antiapoptotic Response of Cardiac Progenitor Cells to TNF-α. In order to rule out any significant baseline difference in the differentiation potential of male versus female CDCs, we performed a preliminary real-time PCR gene expression screening for a panel of markers of cardiovascular commitment, stemness, and epithelial-to-mesenchymal transition. No statistically significant differences could be detected between CDCs from males and females (Supplementary Figure 1A available online at https://doi.org/10.1155/2017/4790563).

Then, we investigated possible gender-related differences in TNF-α responsiveness. The effects of TNF-α are mediated by two receptors called TNFR1 and TNFR2. To evaluate the expression of TNF receptors in male/female CDCs, flow cytometry analysis was performed. Interestingly, we found that both TNFR1 and TNFR2 are expressed by CDCs from male and female patients (Figure 1(a), left histogram), albeit in a lower percentage of female cells (Figure 1(a) right histogram) and/or at a global lower expression level, as suggested by the homogeneous peak shift in the representative histogram panel (Figure 1(b)). TNFR1 activation generates reactive oxygen species (ROS) and induces apoptosis [33]. Conversely, TNFR2, although generating ROS-mediated signaling pathways, does not contain a death domain and cannot transmit proapoptotic signals. Its activation leads to cell survival, proliferation, and growth factor production [29]. TNFR1 is expressed ubiquitously on almost all cell types. TNFR2 expression, instead, is restricted to certain cell types including endothelial cells, myocytes, thymocytes, and...
Figure 1: Continued.
human mesenchymal stem cells. Recently, published data have revealed that these two receptors not only function independently but can also influence each other via cross talk between the different signaling pathways initiated by TNFR1 and TNFR2 stimulation [34].

Next, we investigated the effects of TNF-α treatment. CDCs have been reported to release low levels of TNF-α in culture [8], but the in vitro concentration of 100 ng/ml used in the present study far exceeds the amount due to autocrine production. Considering that ROS appear to serve as key mediators involved in TNF-α-induced cellular responses [19], superoxide anion (O₂⁻) and hydrogen peroxide (H₂O₂) levels were measured by flow cytometry at different time points (3, 6, and 24 hours) after TNF-α treatment. After 3 hours of TNF-α treatment, a higher increase of O₂⁻ levels was detectable in stimulated female versus male cells, compared to control (Δ = 6% in males and Δ = 15% in females, p < 0.05 versus control), while H₂O₂ levels were comparable (Δ = 4% in cells from males and Δ = 6% in cells from females) (Figures 1(c) and 1(d)). Gene expression levels for different NADPH oxidase isoforms, which are the main ROS-producing enzymes [35, 36], were comparable between male and female CDCs (Supplementary Figure 1B), thus excluding any baseline difference between the two.

To determine whether ROS production after TNF-α treatment of CDCs exerted an apoptotic or antiapoptotic cell response, apoptosis and cell cycle progression were assessed by flow cytometry. We found that 24 hours after TNF-α treatment, no difference in the percentage of apoptotic cells was detected in both cell lines (Figure 1(e)). Conversely, a significant (p < 0.001) increase in the percentage of cells in S phase of the cell cycle compared to untreated controls was detected in CDCs from females 48 hours after TNF-α treatment whereas no significant changes were observed in CDCs from males after the same treatment protocol (21.0 ± 0.4% versus 19.0 ± 0.5%) (Figure 1(f)). On the basis of these data, we hypothesized that TNF-α, at the concentration here considered, did not exert a proapoptotic effect in CDCs from both male and female patients, suggesting that TNF-α signaling through TNFR2 could be dominant.

This hypothesis was further supported by the analysis of nuclear localization of nuclear factor kappa B transcription factor subunit p65 (NF-κB p65). In fact, nuclear localization is a ROS-dependent process of cell activation that was observable in cells from both male and female patients 3 hours after TNF-α treatment. At this time, NF-κB p65 subunit was found in 44.0 ± 1.9% of cells from males and 60.0 ± 1.5% of cells from females, with a statistically significant difference between them (Figure 1(g)). Figure 1(h) shows two representative images obtained by fluorescence microscopy, indicating control cells with cytoplasmic NF-κB and female cells after 3 h of TNF-α treatment with NF-κB p65 localization. *p < 0.05. **p < 0.001.
network, contributes to cell shape maintenance, cellular contractility, and motility. It exists in a dynamic equilibrium between monomeric G-actin and polymeric F-actin forming actin fibers. Sex differences in actin filament morphology were detectable in CDCs at basal conditions (Figure 2(a)). Numerous ventral stress fibers were clearly visible by static cytometry, that is, fluorescence microscopy, in cells from males whereas transverse arcs were detected in cells from females. Ventral stress fibers generate strong traction forces at the cell base. They lie along the base of the cell, being usually parallel to the direction of migration, and they are attached to the focal adhesions at both ends [38]. Transverse arcs, instead, are curved stress fibers found parallel to the leading edge and are assembled from shorter actin filaments that originate in the lamellipodium. They are contractile and do not attach to focal adhesions [38]. Interestingly, short exposure (3 h) to TNF-α at low concentration induced a clear redistribution of actin filaments, including stress fibers loss and intense lamellipodia formation in both male and female cells (Figure 2(b)). After a longer exposure time (24 h) to TNF-α, these peripheral structures progressively disappeared, whereas stress fibers reappeared (Figure 2(c)). We cannot rule out the possibility that differences in cytoskeletal network between cells from males and females could modulate the cytoplasmic trafficking of molecules such as NF-κB [39].

3.3. TNF-α Influences Cardiac Progenitor Cell Migration Ability. CPCs’ ability to migrate towards a damaged site plays an important role in their regenerative response. To this regard, 24 hours after the scratch on confluent CDC cultures, a significant difference was found between cells from males and females ($p < 0.05$; 36 cells/mm$^2$ for males and 21 cells/mm$^2$ for females) (Figures 3(a) and 3(b)). In particular, treatment with TNF-α at low concentration promoted migration of CDCs. However, this “booster” effect was significant ($p = 0.001$) only for cells from female patients (Figure 3(c)).

4. Conclusions

Modern surgical and medical therapies have been proven to be still unsatisfactory in the optimal prevention and treatment of heart failure. Moreover, in the perspective of personalized medicine, significant insights are gradually suggesting differential pathophysiological responses based on the patient’s sex [40, 41]. This is particularly true for cardiovascular diseases [3, 42] and cardiac regenerative medicine [43], which may ultimately mirror, at least in part, a different potential and/or responsiveness of resident S/PC pools in terms of function and repair. Genetic (e.g., sex chromosomes), epigenetic (e.g., microRNA), or metabolic (e.g., redox regulation) mechanisms should be taken into consideration in order to explain differences between cells from males and females [44–47].

In the present work, we investigated in vitro the differential sex-related biological response of human resident CPCs in the form of CDCs to TNF-α, an inflammatory cytokine implicated in ischemia/reperfusion, whose effects are bidirectional and dependent on the activation of its receptors and on
cytokine levels. TNFR1 activation generates ROS and induces apoptosis, while TNFR2 activation leads to cell survival, proliferation, and growth factor production [19, 48]. In our work, we found that, although both TNFR1 and TNFR2 are expressed by male and female CDCs, the intracellular signaling mostly activated in our experimental conditions is apparently due to TNFR2, since cell cycle progression and cell spreading seem to be improved, whereas cell death remains negligible at the TNF-α concentration considered here. More importantly, we also found that the response to TNF-α significantly differed between CDCs from females and males. In particular, CDCs from females appear more responsive to TNF-α treatment in terms of cell cycle progression and cell migration ability. Our results are in line with reported data, such as greater myocardial protection capacities exerted by female versus male MSCs [43] or paracrine potentiation of MSCs and CPCs by estradiol treatments [49, 50]. Considering the differences in the incidence of cardiovascular diseases in men versus women, these results suggest that cell therapy protocols should take into account the donor sex in order to improve their efficacy. Allogeneic CDC transplantation has been shown to combine beneficial therapeutic effects with negligible effects due to immune issues [17, 51].

Hence, in view of difficulties encountered in the development of this area of research (e.g., difficulties in S/PCs culture, as well as in transplantation protocols and engraftment efficiency), the present report supports the conclusion that TNF-α-stimulated CDCs isolated from heart biopsies of female donors could represent an improved and promising candidate cell population for cardiac regenerative therapy applications.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Walter Malorni, Giacomo Frati, and Isotta Chimenti contributed equally. Giacomo Frati is the inventor of patents WO2005012510 and US 2012021019 A1, “Method for the isolation and expansion of cardiac stem cells from biopsy,” owned by “La Sapienza” University of Rome.
Acknowledgments

The authors would like to thank “Fondazione Roma” for the continuous support. This work was supported by MIUR funding to Isotta Chimenti, by AIRC 18526 to Walter Malorni, and by “La Sapienza” University funding to Giacomo Frati.

References

[1] G. Frati, L. Schirone, I. Chimenti et al., “An overview of the inflammatory signalling mechanisms in the myocardium underlying the development of diabetic cardiomyopathy,” Cardiovascular Research, vol. 113, no. 4, pp. 378–388, 2017.

[2] V. P. Harjola, W. Mullens, M. Banaszewski et al., “Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC),” European Journal of Heart Failure, vol. 19, no. 7, pp. 821–836, 2017.

[3] W. Rosamond, K. Flegal, K. Furie et al., “Heart disease and stroke statistics– 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee,” Circulation, vol. 117, no. 4, pp. e25–e146, 2008.

[4] M. Peruzzi, E. De Falco, A. Abbate et al., “State of the art on the evidence base in cardiac regenerative therapy: overview of 41 systematic reviews,” BioMed Research International, vol. 2015, Article ID 613782, 7 pages, 2015.

[5] R. Gaetani, L. Barile, F. Angelini et al., “Paracrine mechanisms of stem cell reparative and regenerative actions in the heart,” Journal of Molecular and Cellular Cardiology, vol. 50, no. 2, pp. 280–289, 2011.

[6] T. S. Li, K. Cheng, K. Malliaras et al., “Direct comparison of different stem cell types and subpopulations reveals superior paracrine potency and myocardial repair efficacy with cardiosphere-derived cells,” Journal of the American College of Cardiology, vol. 59, no. 10, pp. 942–953, 2012.

[7] S. Maltais, S. J. Jogerst, A. Hatzopoulos et al., “Stem cell therapy for chronic heart failure: an updated appraisal,” Expert Opinion on Biological Therapy, vol. 13, no. 4, pp. 503–516, 2013.

[8] D. Shen, K. Cheng, and E. Marbán, “Dose-dependent functional benefit of human cardiomyoblast transplantation in mice with acute myocardial infarction,” Journal of Cellular and Molecular Medicine, vol. 16, no. 9, pp. 2112–2116, 2012.

[9] E. Messina, L. De Angelis, G. Frati et al., “From ontogenesis to regeneration: learning how to instruct adult cardiac progenitor cells,” Progress in Molecular Biology and Translational Science, vol. 111, pp. 109–137, 2012.

[10] I. Chimenti, E. Forte, F. Angelini, A. Giacomello, and E. Messina, “Towards regenerative therapy for cardiac disease,” Lancet, vol. 379, no. 9819, pp. 933–942, 2012.

[11] L. Chimenti, R. R. Smith, T. S. Li et al., “Durable benefits of cellular postconditioning: long-term effects of allogeneic cardiomyoblast-derived cells infused after reperfusion in pigs with acute myocardial infarction,” Journal of the American Heart Association, vol. 5, no. 2, 2016.

[12] H. Kanazawa, T. Seliou, J. F. Dawkings et al., “Tumor necrosis factor-alpha and cardiovascular diseases,” Italian Heart Journal, vol. 2, no. 6, pp. 408–417, 2001.

[13] L. Lacerda, R. M. Smith, L. Opie, and S. Lecour, “TNNI2-induced cytoprotection requires the production of free radicals within mitochondria in C2C12 myotubes,” Life Sciences, vol. 79, no. 23, pp. 2194–2201, 2006.

[14] Y. Chen, Z. Zou, Z. Wu et al., “TNFα-induced programmed cell death in the pathogenesis of acquired aplastic anemia,” Expert Review of Hematology, vol. 8, no. 4, pp. 515–526, 2015.

[15] C. Fabrizi, F. Angelini, I. Chimenti et al., “Thrombin and thrombin-derived peptides promote proliferation of cardiac progenitor cells in the form of cardiospheres without affecting their differentiation potential,” Journal of Biological Regulators and Homeostatic Agents, vol. 25, 2 Supplement, pp. S43–S51, 2011.

[16] K. G. Aghila Rani and C. C. Kartha, “Effects of epidermal growth factor on proliferation and migration of cardiomyoblast-derived cells expanded from adult human heart,” Growth Factors, vol. 28, no. 3, pp. 157–165, 2010.

[17] P. D’Elia, V. Ionta, I. Chimenti et al., “Analysis of pregnancy-associated plasma protein A production in human adult cardiac progenitor cells,” BioMed Research International, vol. 2013, Article ID 190178, 8 pages, 2013.

[18] A. Oikonomopoulou, K. I. Sereti, F. Conyers et al., “Wnt signaling exerts an antiproliferative effect on adult cardiac progenitor cells through IGFBP3,” Circulation Research, vol. 109, no. 12, pp. 1363–1374, 2011.

[19] F. Pagano, F. Angelini, C. Siciliano et al., “Beta2-adrenergic signaling affects the phenotype of human cardiac progenitor cells through EMT modulation,” Pharmacological Research, 2017, In press.

[20] L. V. Lee and J. M. Foody, “Women and heart disease,” Cardiology Clinics, vol. 29, no. 1, pp. 35–45, 2011.

[21] R. R. Smith, L. Barile, H. C. Cho et al., “Regenerative potential of cardiomyooblast-derived cells expanded from percutaneous...
endomyocardial biopsy specimens,” *Circulation*, vol. 115, no. 7, pp. 896–908, 2007.

[29] C. N. Zeller, Y. Wang, T. A. Markel et al., “Role of tumor necrosis factor receptor 1 in sex differences of stem cell mediated cardioprotection,” *The Annals of Thoracic Surgery*, vol. 87, no. 3, pp. 812–819, 2009.

[30] I. Chimenti, R. Gaetani, E. Forte et al., “Serum and supplement optimization for EU GMP-compliance in cardiospheres cell culture,” *Journal of Cellular and Molecular Medicine*, vol. 18, no. 4, pp. 624–634, 2014.

[31] P. Matarrese, E. Straface, G. Palumbo et al., “Mitochondria regulate platelet metamorphosis induced by opsonized zymosan A - activation and long-term commitment to cell death,” *The FEBS Journal*, vol. 276, no. 3, pp. 845–856, 2009.

[32] C. C. Liang, A. Y. Park, and J. L. Guan, “In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro,” *Nature Protocols*, vol. 2, no. 2, pp. 329–333, 2007.

[33] S. Schutze, V. Tchikov, and W. Schneider-Brachert, “Regulation of TNFR1 and CD95 signalling by receptor compartmentalization,” *Nature Reviews Molecular Cell Biology*, vol. 9, no. 8, pp. 655–662, 2008.

[34] P. J. Naude, J. A. den Boer, P. G. Luiten, and U. L. Eisel, “Tumor necrosis factor receptor cross-talk,” *The FEBS Journal*, vol. 278, no. 6, pp. 888–898, 2011.

[35] K. Bedard and K. H. Krause, “The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology,” *Physiological Reviews*, vol. 87, no. 1, pp. 245–313, 2007.

[36] X. Hu, “Proteolytic signaling by TNFalpha: caspase activation and IkappaB degradation,” *Cytokine*, vol. 21, no. 6, pp. 286–294, 2003.

[37] E. Kassianidou and S. Kumar, “A biomechanical perspective on stress fiber structure and function,” *Biochimica et Biophysica Acta*, vol. 1853, no. 11, Part B, pp. 3065–3074, 2015.

[38] A. Bolshakova, K. E. Magnusson, G. Pinaev, and O. Petukhova, “Functional compartmentalisation of NF-kB-associated proteins in A431 cells,” *Cell Biology International*, vol. 37, no. 4, pp. 387–396, 2013.

[39] N. Mudrovcic, S. Arefin, A. H. Van Craenenbroeck, and K. Kublikiene, “Endothelial maintenance in health and disease: importance of sex differences,” *Pharmacological Research*, vol. 119, pp. 48–60, 2017.

[40] M. Canevelli, F. Quarata, F. Remiddi et al., “Sex and gender differences in the treatment of Alzheimer’s disease: a systematic review of randomized controlled trials,” *Pharmacological Research*, vol. 115, pp. 218–223, 2017.

[41] M. C. Kander, Y. Cui, and Z. Liu, “Gender difference in oxidative stress: a new look at the mechanisms for cardiovascular diseases,” *Journal of Cellular and Molecular Medicine*, vol. 21, no. 5, pp. 1024–1032, 2016.

[42] P. R. Crisostomo, T. A. Markel, M. Wang, T. Lahm, K. D. Lillemoe, and D. R. Meldrum, “In the adult mesenchymal stem cell population, source gender is a biologically relevant aspect of protective power,” *Surgery*, vol. 142, no. 2, pp. 215–221, 2007.
Submit your manuscripts at
https://www.hindawi.com